Multiple defects in negative regulation of the PKB/Akt pathway sensitise human cancer cells to the antiproliferative effect of non-steroidal anti-inflammatory drugs

Biochemical Pharmacology

Volumn 78, Issue 6, 2009, Pages 561-572

  Lincová, Eva ^a   Hampl, Aleš ^b,c   Pernicová, Zuzana ^a   Staršíchová, Andrea ^a   Krčmář, Pavel ^d   Machala, Miroslav ^d   Kozubík, Alois ^a   Souček, Karel ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^d VETERINARY RESEARCH INSTITUTE   (Czech Republic)

Author keywords

Akt2 isoform; Antiproliferative effects; NSAIDs; Protein kinase B Akt; PTEN; SHIP2

Indexed keywords

BETA ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DICLOFENAC; GROWTH DIFFERENTIATION FACTOR 15; INDOMETACIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIROXICAM; PROTEIN BAX; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE SHP 2; SULINDAC SULFIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; COLON CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INDUCTION; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INDOMETHACIN; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651180542     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.001     Document Type: Article

References (46)

1. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13 (2005) 559-583
2. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15 (2001) 2057-2072
3. Rice P.L., Beard K.S., Driggers L.J., and Ahnen D.J. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 64 (2004) 8148-8151
4. Rice P.L., Goldberg R.J., Ray E.C., Driggers L.J., and Ahnen D.J. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res 61 (2001) 1541-1547
5. Yip-Schneider M.T., and Schmidt C.M. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Pancreas 27 (2003) 337-344
6. Ou Y.-C., Yang C.-R., Cheng C.-L., Raung S.-L., Hung Y.-Y., and Chen C.-J. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT. Eur J Pharmacol 563 (2007) 49-60
7. Ho C.C., Yang X.W., Lee T.L., Liao P.H., Yang S.H., Tsai C.H., et al. Activation of p53 signalling in acetylsalicylic acid-induced apoptosis in OC2 human oral cancer cells. Eur J Clin Invest 33 (2003) 875-882
8. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor κB. J Clin Invest 101 (1998) 1163-1174
9. Baek S.J., Kim J.-S., Moore S.M., Lee S.-H., Martinez J., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 67 (2005) 356-364
10. Liou J.-Y., Ghelani D., Yeh S., and Wu K.K. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3ε. Cancer Res 67 (2007) 3185-3191
11. Yang H., Filipovic Z., Brown D., Breit S.N., and Vassilev L.T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2 (2003) 1023-1029
12. Carracedo A., and Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27 (2008) 5527-5541
13. Vara J.A.F., Casado E., de Castro J., Cejas P., Belda-Iniesta C., and Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30 (2004) 193
14. LoPiccolo J., Blumenthal G.M., Bernstein W.B., and Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11 (2008) 32-50
15. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer 2 (2002) 489-501
16. Sharma P.M., Son H.-S., Ugi S., Ricketts W., and Olefsky J.M. Mechanism of SHIP-mediated inhibition of insulin- and platelet-derived growth factor-stimulated mitogen-activated protein kinase activity in 3T3-L1 adipocytes. Mol Endocrinol 19 (2005) 421-430
17. Sattler M., Verma S., Byrne C.H., Shrikhande G., Winkler T., Algate P.A., et al. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol Cell Biol 19 (1999) 7473-7480
18. Hazen A.L., Smith M.J., Desponts C., Winter O., Moser K., and Kerr W.G. SHIP is required for a functional hematopoietic stem cell niche. Blood (2008) blood-2008-02-138008
19. Chu E.C., Chai J., and Tarnawski A.S. NSAIDs activate PTEN and other phosphatases in human colon cancer cells: novel mechanism for chemopreventive action of NSAIDs. Biochem Biophys Res Commun 320 (2004) 875-879
20. Stewart G.D., Nanda J., Brown D.J., Riddick A.C., Ross J.A., and Habib F.K. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. Int J Cancer 124 (2009) 223-232
21. Lee H.C., Park I.C., Park M.J., An S., Woo S.H., Jin H.O., et al. Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 94 (2005) 597-610
22. Lee C., Kim J.-S., and Waldman T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res 64 (2004) 6906-6914
23. T method. Methods 25 (2001) 402-408
24. Pattyn F., Robbrecht P., De Paepe A., Speleman F., and Vandesompele J. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res 34 (2006) D684-D688
25. Dydensborg A.B., Herring E., Auclair J., Tremblay E., and Beaulieu J.-F. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol Gastrointest Liver Physiol 290 (2006) G1067-G1074
26. Sheaff R.J. Regulation of mammalian cyclin-dependent kinase 2. Methods Enzymol 283 (1997) 173-193
27. Sharrard R.M., and Maitland N.J. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cell Signal 19 (2007) 129-138
28. Hanif R., Pittas A., Feng Y., Koutsos M.I., Qiao L., Staiano-Coico L., et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52 (1996) 237-245
29. Cip/WAF1 and promotes cell survival. J Biol Chem 277 (2002) 11352-11361
30. Cip1 degradation. J Biol Chem 277 (2002) 9684-9689
31. Heron-Milhavet L., Franckhauser C., Rana V., Berthenet C., Fisher D., Hemmings B.A., et al. Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding. Mol Cell Biol 26 (2006) 8267-8280
32. Ulrich C.M., Bigler J., and Potter J.D. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6 (2006) 130-140
33. Marijeta K., Sanja K., Duje K., Josip L., Šime S., and Krešmir P. Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. J Cancer Res Clin Oncol 127 (2001) 173-179
34. Dikshit P., Chatterjee M., Goswami A., Mishra A., and Jana N.R. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 281 (2006) 29228-29235
35. Furst D.E. Clinical significance of long versus short serum half-life in NSAIDs-confounding and complicating factors. In: Famaey J.P., and Paulus H.P. (Eds). Therapeutic applications of NSAIDs: subpopulations and new formulations (1992), Informa Health Care 359-372
36. Herrmann J.L., Briones Jr. F., Brisbay S., Logothetis C.J., and McDonnell T.J. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53. Oncogene 17 (1998) 2889-2899
37. WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem J 337 Pt 3 (1999) 607-616
38. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., and Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59 (2001) 901-908
39. Bock Jonathan M., Menon S.G., Goswami P.C., Sinclair L.L., Bedford N.S., Domann F.E., et al. Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. Mol Carcinog 46 (2007) 857-864
40. Dash B.C., and El-Deiry W.S. Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25 (2005) 3364-3387
41. Brazil D.P., Yang Z.-Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 29 (2004) 233-242
42. Yun S.J., Tucker D.F., Kim E.K., Kim M.S., Do K.H., Ha J.M., et al. Differential regulation of Akt/protein kinase B isoforms during cell cycle progression. FEBS Lett 583 (2009) 685-690
43. Vlietstra R.J., van Alewijk D.C.J.G., Hermans K.G.L., van Steenbrugge G.J., and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58 (1998) 2720-2723
44. Ikubo M., Wada T., Fukui K., Ishiki M., Ishihara H., Asano T., et al. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-α-induced insulin resistance in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 296 (2009) E157-E164
45. Sasaoka T., Wada T., Fukui K., Murakami S., Ishihara H., Suzuki R., et al. SH2-containing inositol phosphatase 2 predominantly regulates Akt2, and Not Akt1, phosphorylation at the plasma membrane in response to insulin in 3T3-L1 adipocytes. J Biol Chem 279 (2004) 14835-14843
46. de Groot D.J.A., de Vries E.G.E., Groen H.J.M., and de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol/Hematol 61 (2007) 52-69